It was a delight to catch up with our Expert Faculty Member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), to discuss the recent phase 2 and 3 analyses of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib.
His abstract entitled ‘Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving tofacitinib results from the Phase 2 and Phase 3 Clinical Programs’ (Fr5340) was presented at DDW, 21-23 May 2021.
- What has the tofacitinib UC clinical trial program taught us about the herpes zoster incidence during the induction and maintenance treatment of ulcerative colitis with tofacitinb? (0:17)
- Could you tell us a little about the analysis you presented at the Digestive Disease Week® (DDW) meeting, and its findings? (1:19)
- Which patients have the highest risk of herpes zoster? (3:19)
- What are the limitations of this analysis and what future studies are planned? (4:35)
Disclosures: Gil Y Melmed has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Meyers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!